Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
0.190
Apr 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.12 - 0.29
Open     -
Vol / Avg. 0.00/80,223.00
Mkt cap 24.98M
P/E     -
Div/yield     -
EPS -0.02
Shares 129.64M
Beta 1.08
Inst. own     -

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.88% -53.36%
Return on average equity -72.68% -55.90%
CDP Score - -

Address

700 Collip Cir Suite 114
LONDON, ON N6G 4X8
Canada
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links

Description

Sernova Corp. is a Canada-based clinical-stage company, which is engaged in developing products for the treatment of chronic debilitating diseases using the Cell Pouch system. The Company�s technologies include Cell Pouch System and Sertolin Technology. Cell Pouch System is implantable and scalable medical device. Sertolin technology provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets. The Company�s Cell Pouch system combined with its Sertolin immune protection technology offers therapeutic cells local protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic disease.

Officers and directors

Frank A. Holler Chairman of the Board
Age: 57
Philip M. Toleikis President, Chief Executive Officer, Director
Cathy R. Steiner CPA Chief Financial Officer
George Adams Director
James T. Parsons Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director